Share this article on:

PRELIMINARY RESULTS OF PEG-L-ASPARAGINASE (ONCASPAR) IN THE TREATMENT OF RELAPSED/ REFRACTORY AIDS-RELATED LYMPHOMAS.

Tulpule, Anil; Espina, Byron M.; Palmer, Maria; Schiflett, Joanne; Harvey-Buchanan, Laura; Levine, Alexandra M.

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology: 1 April 1998 - Volume 17 - Issue 4 - p A31
The Second National AIDS Malignancy Conference

USC/Norris Cancer Hospital, Los Angeles, CA 90033

ABSTRACT 80

BACKGROUND: AIDS-lymphoma is the second most common malignancy in patients with HIV infection. First line combination chemotherapy is associated with complete remission in approximately 50%. No standard second line therapy has been defined in relapsed or refractory patients. We wished to explore the efficacy of pegylated L-asparaginase (Oncaspar) in this patient population. Oncaspar has previously shown efficacy against high grade lymphoid malignancies.

METHODS: Four dose levels of Oncaspar are being studied in relapsed/refractory AIDS-NHL. The dose for cohort 1 is 1500 IU/m2 given IM every two weeks.

RESULTS: Thus far, two patients have been accrued. Their characteristics and study results are shown below: Table

Both patients have had biopsy-proven complete disease resolution. Adverse effects consisted of low fibrinogen, prolonged APTT, and moderate fatigue in both; mild nausea, anorexia, and elevated cholesterol in one patient.

CONCLUSION: We conclude that Oneaspar has good preliminary evidence of anti-tumor activity in patients with refractory AIDS-NHL within minimal side effects. Accrual is ongoing.

Back to Top | Article Outline

Section Description

Bethesda, Maryland April 6-8, 1998

Sponsored by the National Cancer Institute

© Lippincott-Raven Publishers.